NCT00052559View on ClinicalTrials.gov

Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

April 30, 2003

Conditions
Adenocarcinoma of the RectumStage II Rectal CancerStage III Rectal Cancer
Interventions
BIOLOGICAL

bevacizumab

Given IV

DRUG

fluorouracil

Given IV

RADIATION

external beam radiation therapy

Undergo external beam radiation therapy

PROCEDURE

therapeutic conventional surgery

Undergo surgery

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (2)

27710

Duke University Medical Center, Durham

02114

Massachusetts General Hospital Cancer Center, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00052559 - Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer | Biotech Hunter | Biotech Hunter